Literature DB >> 28974544

TERT structural rearrangements in metastatic pheochromocytomas.

Trisha Dwight1,2, Aidan Flynn3,4, Kaushalya Amarasinghe5, Diana E Benn6,2, Richard Lupat5, Jason Li5, Daniel L Cameron5,7,8, Annette Hogg5, Shiva Balachander5, Ida L M Candiloro9,10, Stephen Q Wong5, Bruce G Robinson6,2, Anthony T Papenfuss5,7,8,11,12, Anthony J Gill2,13, Alexander Dobrovic9,10,14, Rodney J Hicks5,11, Roderick J Clifton-Bligh6,2, Richard W Tothill15,10,11.   

Abstract

Pheochromocytomas (PC) and paragangliomas (PGL) are endocrine tumors for which the genetic and clinicopathological features of metastatic progression remain incompletely understood. As a result, the risk of metastasis from a primary tumor cannot be predicted. Early diagnosis of individuals at high risk of developing metastases is clinically important and the identification of new biomarkers that are predictive of metastatic potential is of high value. Activation of TERT has been associated with a number of malignant tumors, including PC/PGL. However, the mechanism of TERT activation in the majority of PC/PGL remains unclear. As TERT promoter mutations occur rarely in PC/PGL, we hypothesized that other mechanisms - such as structural variations - may underlie TERT activation in these tumors. From 35 PC and four PGL, we identified three primary PCs that developed metastases with elevated TERT expression, each of which lacked TERT promoter mutations and promoter DNA methylation. Using whole genome sequencing, we identified somatic structural alterations proximal to the TERT locus in two of these tumors. In both tumors, the genomic rearrangements led to the positioning of super-enhancers proximal to the TERT promoter, that are likely responsible for the activation of the normally tightly repressed TERT expression in chromaffin cells.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  TERT; metastatic; pheochromocytoma; rearrangements; whole genome sequencing

Mesh:

Substances:

Year:  2017        PMID: 28974544     DOI: 10.1530/ERC-17-0306

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  23 in total

Review 1.  Super-enhancer function and its application in cancer targeted therapy.

Authors:  Faqing Tang; Zongbei Yang; Yuan Tan; Yuejin Li
Journal:  NPJ Precis Oncol       Date:  2020-02-12

2.  Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.

Authors:  Joakim Crona; Angela Lamarca; Suman Ghosal; Staffan Welin; Britt Skogseid; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-05       Impact factor: 5.678

Review 3.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

4.  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.

Authors:  Patricia L M Dahia; Roderick Clifton-Bligh; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo; Camilo Jimenez
Journal:  Endocr Relat Cancer       Date:  2020-08       Impact factor: 5.678

Review 5.  The systems of metastatic potential prediction in pheochromocytoma and paraganglioma.

Authors:  Yong Wang; Minghao Li; Hao Deng; Yingxian Pang; Longfei Liu; Xiao Guan
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

6.  Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine.

Authors:  Ruth Casey; Hartmut P H Neumann; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

7.  A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing.

Authors:  Sounak Gupta; Chad M Vanderbilt; Yun-Te Lin; Jamal K Benhamida; Achim A Jungbluth; Satshil Rana; Amir Momeni-Boroujeni; Jason C Chang; Tiffany Mcfarlane; Paulo Salazar; Kerry Mullaney; Sumit Middha; Ahmet Zehir; Anuradha Gopalan; Tejus A Bale; Ian Ganly; Maria E Arcila; Ryma Benayed; Michael F Berger; Marc Ladanyi; Snjezana Dogan
Journal:  J Mol Diagn       Date:  2020-12-05       Impact factor: 5.568

Review 8.  Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.

Authors:  C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2021-03-25       Impact factor: 3.943

Review 9.  Beyond the coding genome: non-coding mutations and cancer.

Authors:  Kaivalya Walavalkar; Dimple Notani
Journal:  Front Biosci (Landmark Ed)       Date:  2020-06-01

10.  Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.

Authors:  Suman Ghosal; Shaoli Das; Ying Pang; Melissa K Gonzales; Thanh-Truc Huynh; Yanqin Yang; David Taieb; Joakim Crona; Uma T Shankavaram; Karel Pacak
Journal:  Int J Cancer       Date:  2019-10-11       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.